Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PHR?
Source: PRnewswire
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Phreesia, alleging securities fraud by the company and its executives, with investors needing to apply as Lead Plaintiff by July 13, 2026, highlighting serious concerns over corporate governance and transparency.
- Revenue Downgrade: On March 30, 2026, Phreesia announced significantly reduced revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, indicating substantial market challenges ahead for the company.
- Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, reflecting investor anxiety regarding the company's future prospects and financial health.
- Potential Legal Consequences: The class action lawsuit could expose Phreesia to substantial damages, further impacting its market reputation and investor confidence, underscoring potential risks in compliance and corporate governance practices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.770
Low
24.00
Averages
29.09
High
35.00
Current: 8.770
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Faces Class Action Lawsuit Risks
- Lawsuit Background: Robbins LLP has alerted investors that a class action has been filed on behalf of shareholders who purchased Phreesia (NYSE: PHR) stock between May 8, 2025, and March 30, 2026, alleging that the company misled investors regarding the sustainability of growth in its Network Solutions business, potentially leading to significant investor losses.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia announced a reduction in its fiscal 2027 revenue outlook from a range of $545 million to $559 million down to $510 million to $520 million, indicating a decrease in visibility into future spending commitments and jeopardizing its long-term growth prospects.
- Stock Price Plunge: Following the revenue outlook downgrade, Phreesia's stock price fell from $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026, representing a decline of approximately 27%, reflecting strong market concerns about the company's future performance.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by July 13, 2026, highlighting the importance of corporate governance and executive accountability, as investors seek to recover losses through this litigation.
See More
Phreesia Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Phreesia, alleging violations of federal securities laws from May 8, 2025, to March 30, 2026, aiming to recover damages for investors, indicating a significant loss of confidence in the company's future prospects.
- Demand Slowdown Warning: The complaint highlights that Phreesia is experiencing slowing demand and diminished visibility into key revenue streams, suggesting potential challenges to the company's competitive position in the market, which investors should closely monitor.
- Weakening Marketing Commitments: It also notes that the Company’s Network Solutions segment is facing weakened pharmaceutical marketing commitments, which could lead to revenue declines and further impact shareholder interests and market confidence.
- Investor Action Encouraged: Affected investors are urged to apply to be lead plaintiffs by July 13, 2026, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
Phreesia Faces Class Action Lawsuit for Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors that Phreesia is facing a class action lawsuit for violating §§10(b) and 20(a) of the Securities Exchange Act, involving securities purchasers from May 8, 2025, to March 30, 2026, with a deadline to contact the firm by July 13, 2026.
- False Statement Allegations: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook and confidence in fiscal year 2027 projections, despite uncertainties that could jeopardize revenue targets.
- Investor Losses: Investors suffered damages when the market learned the truth about Phreesia, indicating that the company's public statements were false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultation for affected investors, encouraging them to join the lawsuit to recover losses, while emphasizing that investors are not represented until the class action is certified.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, with a deadline of July 13, 2026, to apply as lead plaintiff.
- Allegation Details: The complaint alleges that Phreesia and its executives violated federal securities laws by failing to disclose the true state of slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal 2027 revenue guidance down to $510-$520 million, a reduction of $35 million to $49 million from the previous range, causing the stock to plummet by 21% to 28%.
- Investor Rights Advocacy: The law firm encourages all investors who suffered losses during the class period to contact them to understand their legal rights, with no costs or obligations associated with participation in the lawsuit.
See More
Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Phreesia, alleging securities fraud by the company and its executives, with investors needing to apply as Lead Plaintiff by July 13, 2026, highlighting serious concerns over corporate governance and transparency.
- Revenue Downgrade: On March 30, 2026, Phreesia announced significantly reduced revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, indicating substantial market challenges ahead for the company.
- Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, reflecting investor anxiety regarding the company's future prospects and financial health.
- Potential Legal Consequences: The class action lawsuit could expose Phreesia to substantial damages, further impacting its market reputation and investor confidence, underscoring potential risks in compliance and corporate governance practices.
See More
Phreesia Accused of Misleading Investors in Class Action
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, alleging the company misled investors about the sustainability of growth in its Network Solutions business.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia lowered its fiscal 2027 revenue outlook from $545 million-$559 million to $510 million-$520 million, indicating reduced visibility into spending commitments from pharmaceutical manufacturers, which negatively impacted market confidence.
- Stock Price Plunge: Following the revenue outlook downgrade, Phreesia's stock price fell from $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026, representing a decline of approximately 27%, reflecting investor concerns about the company's future growth.
- Legal Implications: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by July 13, 2026, highlighting the importance of corporate governance and executive accountability, which may influence future investor confidence.
See More
Phreesia Faces Class Action Lawsuit Risks
- Lawsuit Background: Robbins LLP has alerted investors that a class action has been filed on behalf of shareholders who purchased Phreesia (NYSE: PHR) stock between May 8, 2025, and March 30, 2026, alleging that the company misled investors regarding the sustainability of growth in its Network Solutions business, potentially leading to significant investor losses.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia announced a reduction in its fiscal 2027 revenue outlook from a range of $545 million to $559 million down to $510 million to $520 million, indicating a decrease in visibility into future spending commitments and jeopardizing its long-term growth prospects.
- Stock Price Plunge: Following the revenue outlook downgrade, Phreesia's stock price fell from $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026, representing a decline of approximately 27%, reflecting strong market concerns about the company's future performance.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by July 13, 2026, highlighting the importance of corporate governance and executive accountability, as investors seek to recover losses through this litigation.
See More
Phreesia Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Phreesia, alleging violations of federal securities laws from May 8, 2025, to March 30, 2026, aiming to recover damages for investors, indicating a significant loss of confidence in the company's future prospects.
- Demand Slowdown Warning: The complaint highlights that Phreesia is experiencing slowing demand and diminished visibility into key revenue streams, suggesting potential challenges to the company's competitive position in the market, which investors should closely monitor.
- Weakening Marketing Commitments: It also notes that the Company’s Network Solutions segment is facing weakened pharmaceutical marketing commitments, which could lead to revenue declines and further impact shareholder interests and market confidence.
- Investor Action Encouraged: Affected investors are urged to apply to be lead plaintiffs by July 13, 2026, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
Phreesia Faces Class Action Lawsuit for Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors that Phreesia is facing a class action lawsuit for violating §§10(b) and 20(a) of the Securities Exchange Act, involving securities purchasers from May 8, 2025, to March 30, 2026, with a deadline to contact the firm by July 13, 2026.
- False Statement Allegations: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook and confidence in fiscal year 2027 projections, despite uncertainties that could jeopardize revenue targets.
- Investor Losses: Investors suffered damages when the market learned the truth about Phreesia, indicating that the company's public statements were false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultation for affected investors, encouraging them to join the lawsuit to recover losses, while emphasizing that investors are not represented until the class action is certified.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, with a deadline of July 13, 2026, to apply as lead plaintiff.
- Allegation Details: The complaint alleges that Phreesia and its executives violated federal securities laws by failing to disclose the true state of slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal 2027 revenue guidance down to $510-$520 million, a reduction of $35 million to $49 million from the previous range, causing the stock to plummet by 21% to 28%.
- Investor Rights Advocacy: The law firm encourages all investors who suffered losses during the class period to contact them to understand their legal rights, with no costs or obligations associated with participation in the lawsuit.
See More
Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Phreesia, alleging securities fraud by the company and its executives, with investors needing to apply as Lead Plaintiff by July 13, 2026, highlighting serious concerns over corporate governance and transparency.
- Revenue Downgrade: On March 30, 2026, Phreesia announced significantly reduced revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, indicating substantial market challenges ahead for the company.
- Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, reflecting investor anxiety regarding the company's future prospects and financial health.
- Potential Legal Consequences: The class action lawsuit could expose Phreesia to substantial damages, further impacting its market reputation and investor confidence, underscoring potential risks in compliance and corporate governance practices.
See More
Phreesia Accused of Misleading Investors in Class Action
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, alleging the company misled investors about the sustainability of growth in its Network Solutions business.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia lowered its fiscal 2027 revenue outlook from $545 million-$559 million to $510 million-$520 million, indicating reduced visibility into spending commitments from pharmaceutical manufacturers, which negatively impacted market confidence.
- Stock Price Plunge: Following the revenue outlook downgrade, Phreesia's stock price fell from $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026, representing a decline of approximately 27%, reflecting investor concerns about the company's future growth.
- Legal Implications: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by July 13, 2026, highlighting the importance of corporate governance and executive accountability, which may influence future investor confidence.
See More
